埃沃特克从布里斯托尔迈耶斯获得了1000万美元,因为其癌症药物进入第一阶段试验,标志着他们2018年合作的首次进展. Evotec earned $10M from Bristol Myers as its cancer drug entered Phase 1 trials, marking first progress from their 2018 collaboration.

埃沃特克在BMS-986506的第一阶段临床试验开始后,从布里斯托尔·迈耶斯·史奎伯获得了1000万美元的里程碑性支付. 这是一种针对晚期癌的分子粘合剂药物. Evotec received a $10 million milestone payment from Bristol Myers Squibb after the start of a Phase 1 clinical trial for BMS-986506, a molecular glue drug targeting advanced kidney cancer. 通过使用Evotec的AI驱动型奥米克平台开发的疗法旨在利用身体自然处置系统降解以前无法治疗的癌症蛋白质. The therapy, developed using Evotec’s AI-powered omics platforms, aims to degrade previously undruggable cancer proteins by harnessing the body’s natural disposal system. 这标志着2018年启动并于2022年扩展的合作伙伴关系中首次临床进展,旨在开发癌症和其他疾病的蛋白质降解疗法. This marks the first clinical advancement from a collaboration launched in 2018 and expanded in 2022 to develop protein degradation therapies for cancer and other diseases.